Filter
503
Text search:
nucleic
Acid
Featured
Recommendations
85
New Publications
133
Language
Document type
No document type
258
Guidelines
127
Studies & Reports
52
Manuals
37
Fact sheets
13
Strategic & Response Plan
5
Training Material
4
Infographics
3
Situation Updates
2
Resource Platforms
1
Videos
1
Countries / Regions
India
31
Western and Central Europe
17
Global
13
Africa
11
Eastern Europe
11
South Africa
7
Liberia
6
Ethiopia
6
Latin America and the Carribbean
6
Nigeria
5
Nepal
5
Tanzania
5
Rwanda
5
Brazil
5
Myanmar / Burma
5
East and Southern Africa
5
West and Central Africa
5
Ukraine
4
Angola
4
Eastern Europe and Central Asia
4
Asia
4
Russia
4
Sierra Leone
3
Congo, Democratic Republic of
3
Germany
3
Zambia
3
Bangladesh
3
Argentina
3
Namibia
3
Peru
3
Middle East and North Africa
3
Guinea
2
Senegal
2
Uganda
2
Philippines
2
Pakistan
2
Kenya
2
China
2
Mozambique
2
Vietnam
2
Portugal
2
Côte d’Ivoire / Ivory Coast
1
USA
1
Cameroon
1
South Sudan
1
Afghanistan
1
Turkey
1
Syria
1
Chad
1
Cambodia
1
Indonesia
1
Colombia
1
Botswana
1
El Salvador
1
Sri Lanka
1
South–East Asia Region
1
Bhutan
1
Timor Leste/ East Timor
1
Moldova
1
Georgia
1
France
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
109
Clinical Guidelines
95
Pharmacy & Technologies
32
Key Resources
13
Public Health
12
Women & Child Health
12
Capacity Building
2
Toolboxes
TB
102
COVID-19
86
HIV
65
Rapid Response
38
NTDs
24
Ebola
20
Zika
16
AMR
12
Refugee
11
Pharmacy
11
Polio
5
Planetary Health
4
Caregiver
3
Conflict
2
Natural Hazards
1
Specific Hazards
1
Global Health Education
1
Health Financing Toolbox
1
NCDs
1
Handbook For Clinical Management Of Dengue
recommended
Clinical management handbook
This publication is an updated version of the Management of Tuberculosis and HIV Coinfection clinical protocol released in 2007 by the WHO Regional Office for Europe. It is intended for all health care workers involved in preventing, diagnosing, treating and caring for people living with TB and HIV
...
A global Review of evidence and practice
Second Edition
AIDS Medicines and diagnostics services
July 2015
This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of multidrug-resistant tuberculosis and e
...
2nd edition.
Like the original, this second edition of the guidance aims to inform the revision of existing national guidelines and standards for managing Tuberculosis (TB), many of which include guidance on children. It includes recommendations, based on the best available evidence, for improving
...
The TB section of the toolkit presents selected (a) programmatic output and (b) outcome and impact indicators for TB. In addition to recommended monitoring programs and measuring the outcomes and impact of TB programs, indicators for the strengthening of health systems, strengthening of community sy
...
Preliminary version for country introduction
5th edition.
guidance for health managers, health workers, and activists
The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV gen
...
The purpose of this pocketbook is to provide clear guidance on current best management practices for VHF across health-care facilities
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child
...
This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte
...
